Cancer immunotherapies: advances and bottlenecks.

Rui R, Zhou L, He S. · 2023

Read Cancer immunotherapies: advances and bottlenecks. by Rui R, Zhou L, He S. (2023) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc10484345.txt.

Introduction

Rui, Zhou, and He reviewed cancer immune therapy in 2023, from fresh gains to hard limits. Such therapy primes the patient's own immune system to fight a tumour. Cells that creep into a tumour can help or hinder that fight. Their acts shape how well a tumour hides from attack.

Three main routes lead the field, Rui reports. Brake-lifting drugs free immune cells to strike. Vaccines teach the system to spot tumour marks. Cell transfer grows a patient's own cells in a lab and returns them in force. Each route has shown real wins in clinics. Each also faces caps, from side effects to tumours that adapt. The review maps those caps in plain terms.

Catalog record

CREATORRui R, Zhou L, He S.
YEAR2023
COLLECTIONPAPERS
FORMATTXT
FILE SIZE93 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC10484345

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Cancer immunotherapies: advances and bottlenecks By Rui Rui, Liqun Zhou, Shiming He Published in: Frontiers in Immunology DOI: 10.3389/fimmu.2023.1212476 ABSTRACT Immunotherapy has ushered in a new era in cancer treatment, and cancer immunotherapy continues to be rejuvenated. The clinical goal of cancer immunotherapy is to prime host immune system to provide passive or active immunity against malignant tumors. Tumor infiltrating leukocytes (TILs) play an immunomodulatory role in tumor microenvironment (TME) which is closely related to immune escape of tumor cells, thus influence tumor progress. Several cancer immunotherapies, include immune checkpoint inhibitors (ICIs), cancer vaccine, adoptive cell transfer (ACT), have shown great efficacy and promise. In this review, we will summarize the recent research advances in tumor immunotherapy, including the molecular mechanisms and clinical effects as well as limitations of immunotherapy. INTRODUCTION Cancer remains one of the most incurable diseases in the world. Before the 21st century, the main treatments for cancer were surgical resection, radiotherapy, and chemotherapy. Theoretically, cancer can be cured if the tumor tissue is completely removed, however, many cancers have metastasized before they are detected, and most surgical resections are radical removal of the entire organ, causing a certain degree of damage to the patient. Although radiotherapy can kill most of the tumor cells using high doses of radiation, most of the tumor cells will still remain micrometastases, which are difficult to be thoroughly eradicated. Early chemotherapy mainly directly targets on DNA strands, such as platinum compounds and antimetabolites blocking DNA replication and inducing DNA damage. Subsequently derived chemotherapeutic agents center on inhibiting enzymes involved in DNA replication and mitosis, such as camptothecin, anthracyclines, vincristine and paclitaxel. Despite the satisfactory efficacy of chemotherapy, it inevitably damages the patient’s immune system and reduces the quality of life. More than a century ago, immunological approaches to cancers were first suggested when physicians observed that advanced cancers occasionally faded completely after acute bacterial infections. Immunotherapy has revolutionized cancer treatment and led to a deeper understanding of tumors: treatment of tumors should not only target cancer cells but should take the entire tumor microenvironment (TME) into account. Although the immune system has a complex array of mechanisms to detect and destroy cancer cells, however, tumor cells are deteriorated from autologous epithelial cells and therefore have very low antigenicity and are not easily recognized by the immune system. Although some cancer cells can be recognized by the immune system, some mechanisms inherent in tumor cells help cancer evade the attack of the immune system, which is clearly explained by the concept of cancer immune editing, which emphasizes the dual role of the immune system in suppressing tumor growth while also shaping tumor immunogenicity, describing the process of tumorigenesis using a 3-step process: elimination, equilibrium and escape (1). Immune escape is one of the ten new features of tumors. Although initially cancer cells can be effectively monitored and recognized by the immune system, however, due to the immune-editing effects of cancer, they will eventually enter an immune escape state where the tumor will instead use the immune system to accomplish faster metastasis (2). Tumor immune escape is also one of the bottlenecks in improving the efficacy of current tumor therapy. The mechanism of tumor immune escape is complicated but can be summarized as two aspects: one is the immune escape mediated by tumor cells themselves, such as the absence of major histocompatibility complex (MHC) or co-stimulatory molecules of tumor cells, reduced immunogenicity of tumor antigens, and down-regulation of the expression of genes related to antigen presentation. Second, changes in the function of the body’s immune system, such as the failure of the immune system to recognize low levels of tumor-associated antigens in the early stage of tumorigenesis, the suppression of cellular tolerance and function to tumor-associated antigens caused by myeloid-derived suppressor cells (MDSC), regulatory cells (Treg) and tumor-associated macrophages, and the failure of specialized antigen-presenting cell function (3). Immune cells are the cellular basis of immunotherapy, and in some highly immune infiltrated tumors, tumor infiltrating leukocytes (TILs) can reach more than 40% (4). Therefore, understanding immune infiltration in TME is key to improving response rates and developing new cancer immunotherapy strategies. Immune cells are the cellular basis of immunotherapy, and in some highly immune infiltrated tumors, tumor infiltrating leukocytes (TILs) can reach more than 40% (4). Therefore, understanding immune infiltration in TME is key to improving response rates and developing new cancer immunotherapy strategies. Although some tumours, such as glioblastoma, have low immune cell infiltration and are referred to as “cold” tumors, there are immunotherapeutic approaches aimed at increasing and activating TILs in the TME of cold tumors to allow more effective antitumor immunity (5). Immunotherapy, which aims to boost the autoimmune system to remove malignant cells, is a landmark breakthrough in cancer treatment. Despite limited response rates, multiple cancer types have shown sustained clinical responses to immunotherapy (6–8). Several immunotherapies, including immune checkpoint inhibitors (ICIs), cancer vaccine, adoptive cell transfer (ACT), oncolytic virus therapy (OVT), have achieved inspiring results, however, all these treatments in the clinical practice have their own limitations. IMMUNE CHECKPOINT INHIBITORS Within the tumor, effector T cells have reduced cytokine expression and effector capacity and are resistant to reactivation, a state known as “T-cell exhaustion”. Exhausted T cells highly express a variety of inhibitory surface molecules that effectively prevent T cell activation (9), including cytotoxic T lymphocyte antigen 4 (CTLA-4), programmed death 1 (PD-1), lymphocyte activation gene-3 (LAG-3), and T cell immunoglobulin and ITIM domain (TIGIT). These inhibitory surface molecules are defined as immune checkpoints. Immune checkpoint blockade (ICB), which targets regulatory pathways in T cells by immune checkpoint inhibitors (ICIs) to enhance anti-tumor immune responses, has shown improved survival over conventional cancer therapy for various cancers and provided a new weapon against tumors. Compared to previous therapies which target to inherent properties of cancer cells, ICB leads to more durable anticancer response via boosting anti-tumor response of immune system (10). Currently various ICIs have been approved by FDA ( Table 1 ), such as ipilimumab and nivolumab. Newly identified immune checkpoints would also be summarized in this section. [Table: Summarized immune checkpoint inhibitors approved by FDA or under clinical trials.] CTLA-4 Cytotoxic T lymphocyte antigen 4 (CTLA-4) (CD152) and CD28 are homologous receptors expressed on the surface of CD4+ and CD8+ T cells that mediate opposite functions in T cell activation. Recognition of TCR and peptide-MHC class I complexes (pMHC-I) alone is not sufficient to fully activate T cells, activation by co-stimulatory signals is also required, among which the interaction of CD28 and its ligands B7-1 (CD80) and B7-2 (CD86) is most important. The intracellular domain of CD28 contains the YMNM motif and PYAP motif, which can bind to adaptor proteins and several kinases. Some proteins bind to either or both motifs though SH2 or SH3 domain interactions, thereby stimulate IL2 transcription which is mediated by CD28-dependent activation of nuclear factor of activated T cells (NFAT), activator protein 1 (AP-1) and nuclear factor-κB (NF-κB) family transcription factors (24). However, CTLA-4 has much higher affinity and avidity for both CD80 and CD86, binds to CD80/86 and activates intracellular signals that ultimately cause IL-2 downregulation, apoptosis, and anergy (25). CTLA-4 is bivalent homodimer while CD28 is monovalent homodimer, by the

Read the complete text